Merck & Co Inc

NYSE:MRK  
71.65
-0.32 (-0.44%)
5:28:11 PM EDT: $71.40 -0.25 (-0.35%)
Other Pre-Announcement

Merck Sees Potential U.S. Authorization For COVID-19 Drug Molnupiravir Before Year-End

Published: 09/13/2021 16:36 GMT
Merck & Co Inc (MRK) - Merck CEO Says Business Development is a High Priority; Will Continue to Be Appropriately Aggressive in Evaluating Potential Targets - Morgan Stanley Conf.
Merck CEO Says Completely Open to Looking at Larger Deals and Looking for Assets That Are Later in Development- Morgan Stanley Conf.
Merck CEO Says Co Expects Clinical Data on Covid-19 Drug Molnupiravir in 2h 2021, and Potential for Eua Before Year End - Morgan Stanley Conf.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).